Q-omics provides the consensus-scored TRNAU1AP profile across patient tissues and cancer cell-line models. TRNAU1AP expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TRNAU1AP is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, TRNAU1AP protein abundance shows 20,054 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, HNSC, and GBM as cancer lineages where TRNAU1AP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRNAU1AP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRNAU1AP survival associations across molecular data types. TRNAU1AP RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRNAU1AP RNA expression–survival associations across cancer types. High TRNAU1AP expression shows unfavorable associations in ACC, LIHC, LGG and PRAD, but favorable associations in UCEC and READ. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TRNAU1AP RNA expression.
This table summarizes TRNAU1AP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TRNAU1AP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRNAU1AP shows lower tumor expression in KICH and higher tumor expression in HNSC, KIRC, LIHC, THCA and BLCA. The HNSC box plot shows higher TRNAU1AP RNA expression in tumor versus normal tissue (log2 FC = +0.805, t-test p < 0.001).
This table shows molecular features associated with TRNAU1AP in patient tissues and cancer cell lines. In patient samples, TRNAU1AP shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TRNAU1AP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
